108 related articles for article (PubMed ID: 18280477)
1. Intravenous leiomyomatosis treated with aromatase inhibitor therapy.
Biri A; Korucuoglu U; Zumrutbas N; Tiras B; Guner H
Int J Gynaecol Obstet; 2008 Jun; 101(3):299-300. PubMed ID: 18280477
[No Abstract] [Full Text] [Related]
2. Successful management of a leiomyomatosis peritonealis disseminata with an aromatase inhibitor.
Takeda T; Masuhara K; Kamiura S
Obstet Gynecol; 2008 Aug; 112(2 Pt 2):491-3. PubMed ID: 18669776
[TBL] [Abstract][Full Text] [Related]
3. Effect of the aromatase inhibitor anastrozole on uterine and leiomyoma Doppler blood flow in patients scheduled for hysterectomy: a pilot study.
Brito LG; Candido-dos-Reis FJ; Magario FA; Sabino-de-Freitas MM
Ultrasound Obstet Gynecol; 2012 Jul; 40(1):119-20. PubMed ID: 22102490
[No Abstract] [Full Text] [Related]
4. Intravenous leiomyomatosis treated with radical hysterectomy and adjuvant aromatase inhibitor therapy.
Mizoguchi C; Matsumoto H; Nasu K; Arakane M; Kai K; Narahara H
J Obstet Gynaecol Res; 2016 Oct; 42(10):1405-1408. PubMed ID: 27436168
[TBL] [Abstract][Full Text] [Related]
5. Durable complete remission with aromatase inhibitor therapy in a patient with metastatic uterine carcinosarcoma with poor performance status and coagulation disorders: a case report.
Martin-Romano P; Jurado M; Idoate MA; Arbea L; Hernandez-Lizoain JL; Cano D; Paramo JA; Martin-Algarra S
J Med Case Rep; 2017 Apr; 11(1):115. PubMed ID: 28424084
[TBL] [Abstract][Full Text] [Related]
6. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
[TBL] [Abstract][Full Text] [Related]
7. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients.
Hilário SG; Bozzini N; Borsari R; Baracat EC
Fertil Steril; 2009 Jan; 91(1):240-3. PubMed ID: 18249392
[TBL] [Abstract][Full Text] [Related]
8. Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor.
Hardman MP; Roman JJ; Burnett AF; Santin AD
Obstet Gynecol; 2007 Aug; 110(2 Pt 2):518-20. PubMed ID: 17666649
[TBL] [Abstract][Full Text] [Related]
9. [Endometrial stromal sarcoma: complete response to therapy with aromatase-inhibitor, anastrozole].
Lisianskaia AS; Manikhas GM; Fadeeva EP; Fedosenko KV; Tapil'skaia NI
Vopr Onkol; 2010; 56(1):91-3. PubMed ID: 20361625
[No Abstract] [Full Text] [Related]
10. Aromatase inhibitors in recurrent ovarian endometriomas: report of five cases with literature review.
Lall Seal S; Kamilya G; Mukherji J; De A; Ghosh D; Majhi AK
Fertil Steril; 2011 Jan; 95(1):291.e15-8. PubMed ID: 20579642
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.
George S; Feng Y; Manola J; Nucci MR; Butrynski JE; Morgan JA; Ramaiya N; Quek R; Penson RT; Wagner AJ; Harmon D; Demetri GD; Krasner C
Cancer; 2014 Mar; 120(5):738-43. PubMed ID: 24222211
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of letrozole in the breast cancer treatment continuum.
Monnier A
Breast; 2006 Feb; 15 Suppl 1():S1-2. PubMed ID: 16500234
[No Abstract] [Full Text] [Related]
13. Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women.
Duhan N; Madaan S; Sen J
Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):329-32. PubMed ID: 24103533
[TBL] [Abstract][Full Text] [Related]
14. The effect of anastrazole on symptomatic uterine leiomyomata.
Varelas FK; Papanicolaou AN; Vavatsi-Christaki N; Makedos GA; Vlassis GD
Obstet Gynecol; 2007 Sep; 110(3):643-9. PubMed ID: 17766612
[TBL] [Abstract][Full Text] [Related]
15. [The use of letrozole in ovarian cancer].
Livshits MA; Vasil'ev BV; Guseĭnov KD
Vopr Onkol; 2014; 60(3):388-91. PubMed ID: 25033697
[No Abstract] [Full Text] [Related]
16. Long-term efficacy and safety of aromatase inhibitor use for leiomyomatosis peritonealis disseminata.
Ando H; Kusunoki S; Ota T; Sugimori Y; Matsuoka S; Ogishima D
J Obstet Gynaecol Res; 2017 Sep; 43(9):1489-1492. PubMed ID: 28691239
[TBL] [Abstract][Full Text] [Related]
17. A case of benign metastasizing leiomyoma treated by surgical castration followed by an aromatase inhibitor, anastrozole.
Nasu K; Tsuno A; Takai N; Narahara H
Arch Gynecol Obstet; 2009 Feb; 279(2):255-7. PubMed ID: 18523791
[TBL] [Abstract][Full Text] [Related]
18. Ejaculatory sperm production in non-obstructive azoospermic patients with a history of negative testicular biopsy after the administration of an aromatase inhibitor: report of two cases.
Kyrou D; Kosmas IP; Popovic-Todorovic B; Donoso P; Devroey P; Fatemi HM
Eur J Obstet Gynecol Reprod Biol; 2014 Feb; 173():120-1. PubMed ID: 24295732
[No Abstract] [Full Text] [Related]
19. Regression of choroidal metastases from breast carcinoma using aromatase inhibitors.
Manquez ME; Shields CL; Karatza EC; Shields JA
Br J Ophthalmol; 2005 Jun; 89(6):776-7. PubMed ID: 15923523
[No Abstract] [Full Text] [Related]
20. Promising effect of aromatase inhibitors on recurrent granulosa cell tumors.
Korach J; Perri T; Beiner M; Davidzon T; Fridman E; Ben-Baruch G
Int J Gynecol Cancer; 2009 Jul; 19(5):830-3. PubMed ID: 19574768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
